Study to Evaluate the Pharmacokinetics, Safety, Tolerability of 100 mg Multiple Doses of GLPG0634 in Subjects With Renal Impairment Compared to Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 08 Aug 2018
Price : $35 *
At a glance
- Drugs Filgotinib (Primary)
- Indications Crohn's disease; Rheumatoid arthritis
- Focus Pharmacokinetics
- Sponsors Galapagos NV
- 08 Aug 2018 Results published in the British Journal of Clinical Pharmacology.
- 08 Nov 2015 Results will be presented at the American College of Rheumatology (ACR) Annual Meeting 2015, according to a Galapagos NV media release.
- 21 Jul 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov.